Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell non-Hodgkin lymphoma (30–40%) (Alexander et al., 2007). Although DLBCL is potentially curable with conventional ...
Please provide your email address to receive an email when new articles are posted on . Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which presented results ...
Cancer remains a major health issue and is responsible for one in four deaths in the United States (Zhou et al, 2001; Jemal et al, 2006). The development of multidrug resistance (MDR) to ...
PD-L1 and PD-1 expression profile depending on the microsatellite status and the histological subtype in colorectal carcinomas. This is an ASCO Meeting Abstract from the 2017 Gastrointestinal Cancers ...
(Memphis, Tenn. – August 18 th, 2023) Most new cancer cases are treated with chemotherapy, but humans naturally express proteins that indiscriminately remove chemotherapy drugs from many cells — ...
When cancer cells resist the effects of drugs used for treatment, they can grow and reform tumors, a process known as recurrence or relapse. Sometimes resistance develops quickly, within a matter of ...
Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results